Pharmacotherapy Update
Myqorzo (aficamten)
Myqorzo was approved on December 19, 2025, based on the results of the SEQUOIA-HCM trial for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.
Published online June 10, 2026.
Bookmark this page and check back often for papers published early online.